BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
Go back to BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 3.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.16 | 52 Week High | $1.63 | |||
| Open | $3.16 | 52 Week Low | $0.71 | |||
| Day High | $3.16 | P/E | N/A | |||
| Day Low | $3.16 | EPS | $0.00 | |||
| Volume | 871 | |||||
| BIOLINE RX SP ADR (NASDAQ: BLRX) | Delayed: 3.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.16 | 52 Week High | $1.63 | |||
| Open | $3.16 | 52 Week Low | $0.71 | |||
| Day High | $3.16 | P/E | N/A | |||
| Day Low | $3.16 | EPS | $0.00 | |||
| Volume | 871 | |||||

